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Cytokine Regulation of Periportal Fibrosis in Humans Infected
with Schistosoma mansoni: IFN- Is Associated with Protection
Against Fibrosis and TNF- with Aggravation of Disease1
Sandrine Henri,* Christophe Chevillard,* Adil Mergani,† Patricia Paris,* Jean Gaudart,*
Christophe Camilla,‡ He´lia Dessein,* Felix Montero,‡ Nasr-Eldin M. A. Elwali,†
Osman K. Saeed,§ Mubarak Magzoub,† and Alain J. Dessein2*
Hepatic periportal fibrosis, which affects 5–10% of subjects infected by Schistosoma mansoni, is caused by the T cell-dependent
granuloma that develop around schistosome eggs. Experimental models of infection have shown that granuloma and fibrosis are
tightly regulated by cytokines. However, it is unknown why advanced periportal fibrosis occurs only in certain subjects. The goal
of the present study was to evaluate the cytokine response of S. mansoni-infected subjects with advanced liver disease in an attempt
to relate susceptibility to periportal fibrosis with an abnormal production of cytokines that regulate granuloma and fibrosis.
Fibrosis was evaluated by ultrasound on 795 inhabitants of a Sudanese village in which S. mansoni is endemic: advanced periportal
fibrosis was observed in 12% of the population; 35% of the affected subjects exhibited signs of portal hypertension. Age (odds ratio
(OR), 11.5), gender (OR, 4.2), and infection levels (OR, 2.2) were significantly (p< 0.01) associated with hepatic fibrosis. Cytokines
produced by egg-stimulated blood mononuclear cells from 99 subjects were measured (75 with no or mild fibrosis; 24 subjects with
advanced fibrosis). Multivariate analysis of cytokine levels showed that high IFN- levels were associated with a marked reduction
of the risk of fibrosis (p  0.01; OR, 0.1); in contrast, high TNF- levels were associated with an increased risk (p  0.05; OR,
4.6) of periportal fibrosis. Moreover, infection levels were negatively associated with IFN- production. These results with ob-
servations in experimental models strongly suggest that IFN- plays a key role in the protection of S. mansoni-infected patients
against periportal fibrosis, whereas TNF- may aggravate the disease. The Journal of Immunology, 2002, 169: 929–936.
M illions of people in subtropical countries are infectedby Schistosoma mansoni, which is the most commonhuman schistosome (1). Schistosome worms live in
mesenteric and portal veins of their human host, and schistosome
eggs trapped in hepatic sinusoids induce an inflammatory granu-
loma that prevent toxic substances from diffusing from the eggs to
the surrounding hepatic tissue. Products of the inflammation, in-
cluding molecules released by damaged cells, stimulate the differ-
entiation of stellate cells into myofibroblasts that secrete extracel-
lular matrix proteins (ECMP)3 in the space of Disse (2). The
disease is the consequence of the excessive accumulation of these
matrix components in the periportal space. Fortunately, most in-
fected subjects living in highly endemic areas control the infection
with only minor pathological manifestations. However, in a small
percentage of infected subjects, especially in those with high in-
fections, extended periportal fibrosis (PPF) leads to portal hyper-
tension, varices, and ascites.
The production of ECMP at the site of an inflammation is part
of the normal repair process. It is initiated by molecules released
by insulted tissues and is regulated by a number of cytokines,
among which TGF-, IL-1, IL-6, IL-4, IL-5, IL-10, IL-13,
TNF-, and IFN- are the most important (3, 4). In particular, in
vitro work has shown that IFN- is a strong antifibrogenic cyto-
kine. It inhibits the production of ECMP by stellate cells and in-
creases the collagenase activity of the liver by stimulating metal-
loprotease (MP) synthesis and by inhibiting tissue inhibitors of MP
(TIMP) synthesis (5–9). TGF-, IL-1, and IL-4 are fibrogenic;
they stimulate the differentiation of stellate cells into myofibro-
blasts and they exert effects opposite to those of IFN- on the
synthesis of ECMP and TIMPs (10–12). The roles of IL-4, IL-5,
IL-10, IL-13, TNF-, and IFN- in granuloma and in fibrosis have
been evaluated in experimental models of schistosomiasis. IFN-
was confirmed as the major down-regulator of fibrosis (13),
whereas IL-4 was shown to be strongly proinflammatory (14–16)
and IL-13 was reported to be fibrogenic (17–19). Recent observa-
tions indicate that IL-10 could have the key regulatory role of
controlling excessive Th1 and Th2 polarization of the granuloma-
tous response (20, 21). IL-12, when administered with egg Ags,
stimulates protection against fibrosis by increasing IFN- and
TNF- (22). Finally, TNF- could have protective (23) as well as
proinflammatory and profibrogenic effects (24–26).
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Our group has recently demonstrated in a Sudanese population
in a region endemic for S. mansoni that severe PPF was under the
control of a major genetic locus that is closely linked to IFNGR1
(27), the gene that encodes the -chain of the IFN- receptor. This
finding together with the results of various studies that have shown
the key role of certain cytokines in regulating hepatic fibrosis in
experimental schistosomiasis led us to test whether an imbalance
in the production of the above mentioned cytokines was associated
with advanced PPF in humans. The data strongly support a critical
role of IFN- in protection against PPF, whereas TNF- is shown
to be associated with disease.
Materials and Methods
Study area and study subjects
Study subjects were from Al Taweel, a Sudanese village (900 individuals)
in the Gezira irrigated scheme region that is highly endemic for S. mansoni.
The villagers are migrants who settled 15–20 years ago in the village. They
all came from the same region of west Sudan in which schistosomiasis is
not endemic. The only source of water for the villagers is the canal water,
which is used for drinking, domestic use (baths, washing), and irrigating
the fields. The canal is densely populated by infected snails, and all study
subjects had frequent contacts with contaminated waters for the past 15–20
years. A total of 795 subjects was studied by ultrasound (US).
Selection of subjects for the cytokine study
All subjects with FII or FIII fibrosis were invited to participate in the study.
Only, one case, chosen randomly, was included per nuclear family.
A list of 150 subjects with no fibrosis (F0) or mild fibrosis (FI) was
prepared using the following criteria: 1) 50% of the subjects should be25
years to insure that these unaffected subjects were unlikely to develop FII
or FIII fibrosis years later. FII peaks sharply in that population at 20–25
years of age; 2) only one case per nuclear family (chosen randomly).
A total of 78 subjects with F0-FI and 25 with FII-FIII accepted to donate
blood. The others either refused or were absent, working in the field, or
could not spend a day in the city in which the laboratory work was
performed.
Among these 103 subjects, 45 were 10–20 years, 30 were 21–35 years,
and 28 were 35 years; 52% of the subjects were males. The proportion
of subjects with advanced fibrosis was 8.8, 40, and 46% in the 10- to
20-year, 21- to 35-year, and 35-year age groups, respectively.
Of these 103 blood samples, complete cytokine data were obtained on
99 samples (75 FO-FI and 24 FII-FIII).
US evaluation
PPF was evaluated by US using an Aloka SSD 500 Echo camera and a 3.5
MHz convex probe according to World Health Organization guidelines
(28). These guidelines were used rather than more recent ones because they
allowed us to demonstrate that a discrete step in FFP was controlled by a
major genetic locus (27). One objective of this study was to find out
whether differences in cytokine production were associated with these ge-
netically controlled phenotypes. Liver size, peripheral portal vein branches
(PPB), the degree of PPF, thickness of the walls of PPB, spleen size, and
splenic vein diameter were assessed. Portal vein diameter (PV) was mea-
sured at its entrance to the porta hepatis at the lower end of the caudete
lobe, on subjects who had fasted for 8–10 h. Thickening of secondary
periportal branches was observed for all subjects with FI to FIII, and the
thickness tended to increase with fibrosis grade.
PPF was graded 0-III. Grade 0 (F0) corresponds to normal liver with no
thickening of the wall of PPB. PPB diameter (outer to outer) is 2–3 mm.
Grade I (FI) corresponds to a pattern of small stretches of fibrosis around
secondary portal branches. This patchy fibrosis usually yields a “fishes in
the pond” appearance. PPB diameter is 4 mm. Grade II (FII) corresponds
to continuous in addition to patchy thickening of PPB. Most second order
branches appear as long segment of fibrosis; PPB diameter is 5–6 mm.
Gallbladder wall thickness may be 4 mm. Grade III (FIII) corresponds to
wall thickening of almost all PPB. Fibrosis reaches the surface of the liver;
in some branches, the lumen is occluded. Gallbladder wall thickness is
usually above normal (2–4 mm).
Parasitological procedures and treatment
Egg counts were performed by Kato’s method on at least four stools col-
lected on different days. All subjects were treated with Praziquantel. This
treatment was repeated once to improve the cure, as assessed by three stool
exams 3 mo after treatment. This second treatment was sufficient to cure all
study subjects, as assessed by egg excretion in the feces. Plasmodium fal-
ciparum infections monitored by blood smears showed that malaria was
endemic in that village. Treatment of malaria was given by local doctors at
the local outpatient clinic. Transmission was seasonal. The study was con-
ducted during the dry season outside the transmission period. At the time
of examination (clinical and US), none of the patients showed signs of
malaria. Note: 1) in these subjects, splenomegaly correlated with PPF (29);
2) neither splenomegaly nor hepatomegaly entered in the definition of the
clinical phenotype that was studied in the present study.
Ag preparation
Frozen pellets of S. mansoni eggs were suspended in PBS and sonicated
twice for 10 min in PBS, on ice. Insoluble material was removed by ul-
tracentrifugation at 105  g for 1 h at 4°C. Supernatants (soluble egg Ags
(SEA)) containing 1–1.5 mg/ml protein were stored at 70°C until use.
Cytokine production and titration
PBMC were isolated from heparinized venous blood by Ficoll-Hypaque gra-
dient sedimentation (400  g, 30 min, 18°C). PBMC were washed twice in
RPMI medium containing 10 g/ml gentamicin, and then suspended in the
same medium supplemented with 50 M 2-ME, 2 mM L-glutamine, 10%
FBS, 10 mM HEPES, and 100 g/ml sodium pyruvate and distributed at
5  106 cells/well in 24-well culture plates. After the addition of Ag (2.5
g/ml SEA), cells were incubated at 37°C in a 5% CO2 atmosphere in a
humidified incubator. Supernatants were collected on days 2 and 5, and
cytokines were titrated by ELISA (IFN-, IFN-, IL-5, TNF-) or by the
Simultaneous Multianalyte Reagent Technology method (IL-1, IL-4,
IL-6, IL-10, and IL-12p40). For ELISA, titration plates were coated over-
night at 4°C with 4 g/ml anti-human IFN- mAb (Mabtech, Nacka, Swe-
den), 2 g/ml anti-human IL-5 mAb (BD PharMingen, San Diego, CA), 2
g/ml anti-human TNF- mAb (R&D Systems, Abingdon, U.K.) diluted
in carbonate buffer 0.1 M, pH 9.6. Then plates were incubated for 2 h with
PBS-3% BSA, and washed twice with PBS-0.05% Tween 20. Culture su-
pernatants were added and incubated overnight at 4°C. After three washes,
plates were incubated for 2 h at room temperature with 0.5 g/ml biotin-
ylated anti-human IFN- Ab (Mabtech), 2 g/ml biotinylated anti-human
IL-5 Ab (BD PharMingen), or 100 ng/ml biotinylated anti-human TNF-
Ab (R&D Systems) diluted with PBS-3% BSA. After three washes, plates
were incubated for 2 h at room temperature with 1 g/ml streptavidin-
alkaline phosphatase (Jackson ImmunoResearch Laboratories, West
Grove, PA) diluted with PBS-3% BSA. After four washes, 200 l 1 mg/ml
p-nitrophenyl solution was added. OD was read at 405 nm. Standards were
recombinant proteins. IFN- was titrated using a kit (Immunotech, Mar-
seille, France).
The Simultaneous Multianalyte Reagent Technology method is a flow
cytometric immunoassay performed on fluorescent and Ab-coated micro-
spheres (30), allowing the simultaneous titration of IL-1, IL-4, IL-6, IL-
10, and IL-12p40, with a sensitivity of 0.5–1.5 pg/ml. It has been described
extensively previously (31). The flow cytometer microsphere-based assay
uses green fluorescence intensity measurement to discriminate between
microspheres. Microspheres in each category are coated with a specific
anticytokine mAb. The red fluorescent intensity allows the sensitive quan-
titation of the immune complexes formed at the surface of each micro-
sphere. The reliability of the assay has been improved with an internal
standard for the adjustment of the fluorescent signal from anticytokine
microspheres in each sample. The analytical performance of the assay has
been described in an investigation on the cytokine profiles (IL-4, IL-6,
IL-10, IL-12, IFN-, and TNF-) of in vitro activated whole blood from
atopic and nonatopic patients (31). A total of 50 l sample was incubated
for 2 h with 10 l mixture of coated microspheres (100 g/ml) and 50 l
mixture of biotinylated Abs (1 g/ml) at room temperature with shaking.
After two washes, 100 l (0.5 g/ml) of streptavidin-PE-Cy5 conjugate
was incubated with the microspheres for 30 min at room temperature with
shaking, and washed twice. The microspheres were then analyzed on a
Coulter EPICS XL/MCL flow cytometer (Beckman Coulter, Miami, FL).
The instrument was carefully set to provide optimal discrimination for
FL1-coded microspheres and the optimal range for FL4 binding. FCS file
processing and subsequent calculation of the immunoassay data were per-
formed automatically with a postanalysis software package developed
in-house.
Statistical analysis
The phenotypes under study (advanced PPF and advanced PPF  enlarged
PV) depend on several covariates; some of these covariates could be con-
founder for the effect of others, and their effect on the phenotype must be
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tested simultaneously (multivariate analysis). We therefore first tested in-
dependently (nonparametric Wilcoxon ranking test) the association of the
various covariates that may influence the phenotype. The results are pre-
sented (see Table II) that shows p values 0.2 because p values between
0.05 and 0.2 may indicate a trend for association that may be suggestive for
other studies. In the multivariate analysis, we tested simultaneously all
covariates. The multivariate method used in this study is logistic regression
that specifies a regression relationship between the probability of an indi-
vidual to develop advanced fibrosis and various covariates, as follows:
PM/X1,X2,. . . Xp 1 exp ((  	iXi)))1
where P(M/X1,X2,. . . Xp) is the probability of being affected knowing X1
to Xp covariates;  and  are constants and estimated in the analysis. The
analysis tests whether i is significantly different from zero. Note that
exp{i} is the odds ratio (OR) associated with the covariate Xi, which
measures the strength of the association between Xi and the phenotype,
taking into account (adjusted to) the other covariates. With the stepwise
procedure, one can select the covariates significantly ( p 0.05) associated
with the risk of being affected.
Univariate analysis of the data, performed by the Wilcoxon test, is
shown (see Table II). Data analysis in other tables was performed by as-
cendant stepwise (likelihood ratio procedure) logistic regression on the
probability of being affected by PPF. The affected phenotypes were FII-III
or FII-III associated with signs of portal hypertension (PV  13 mm in
females and PV  14 mm in males). The nonaffected phenotype was F0-I
with normal PV.
The regression analysis classes were defined as follows: gender (female,
male), ethnic group (Tama-Messeria; Rawashda), and infection levels:
three classes that were defined to include all negative subjects in the same
groups (6 eggs/g) and to have an equal number of subjects in the two
other groups (7–48 eggs/g and 48–500 eggs/g) (see Table II). Cytokine
classes were defined with the median value of the cytokine titer to have two
classes (low and high) of equal size. Age classes were based on the U.S.
evaluation of this population, which showed a marked difference in fibrosis
prevalence between the classes of age: 10–20, 21–35, and 35 years (29).
The same classes were used throughout this work in tables and figures. The
statistical SPSS software (version 10.0; Chicago, IL) was used for this
analysis.
Results
Pathological manifestations in study subjects
Previous studies have shown that PPF in human schistosomiasis
can be accurately evaluated by US, and guidelines have been ed-
ited by World Health Organization to increase consistency of ob-
servations between observers (28, 32). PPF (FII or FIII) was ob-
served in 12% of the 795 subjects; the other subjects had normal
liver or mild hepatic fibrosis. Signs of portal hypertension were
observed in 35% of FII and in all FIII subjects. Splenomegaly was
observed in all groups (F0, I, II, III), but it was more frequent in
subjects with PPF. FII and FIII were associated with a smaller left
lobe of the liver, as determined by US (29).
Stepwise logistic regression analysis was performed with the
variables age, gender, and infection levels, which could influence
disease development (this work and Ref. 29), and the probability
of developing PPF (FII-III) in the whole population (Table I). All
three variables were significantly ( p  0.01) associated with the
probability of developing PPF. OR measure the strength of the
association of covariates with fibrosis; they are adjusted on other
covariates with significant association with disease. Thus, OR for
infection levels are adjusted on age and gender. OR are a good
approximation of the relative risk associated with the covariates.
Thus, the relative risk of PPF was 4 times higher in males than in
females, 14 times higher in the35 years of age than in the 10–20
years of age, and higher in subjects with the highest infections than
in subjects with the lowest infections. Contrary to infection levels,
age and gender were important explicative variables for a pheno-
type combining PPF and portal hypertension (Table I). There was
no significant association between either one of the two pheno-
types and ethnic groups.
Cytokine production by PBMCs
The levels of cytokine produced by SEA-stimulated PBMC of FII-
III subjects and F0-I subjects are shown in Table II. IL-12 and
IFN- levels were under detection levels in most cultures and are
not presented. At the time this study was performed, there was no
evidence that IL-13 had a fibrogenic effect in schistosomiasis; for
this reason, IL-13 was not evaluated in this study. Table II gives
the cytokine titers in 48- and 120-h cultures of cells stimulated
with SEA and in 48-h cultures of unstimulated cells. Data are
shown by age classes for both clinical groups. Differences between
the two clinical groups were analyzed by the Wilcoxon ranking
test that included either all age groups (p1 value) or subjects older
than 20 years (p2 value). The 75% values are given only when the
statistical test gave a significant (p1 or p2 0.05) or a suggestive
(p1 or p2 0.2) p value. In SEA-stimulated cultures, only IFN-
levels were different between the two clinical groups; this differ-
ence was greater when the analysis was performed on data from
adults 20 years. Subjects with advanced fibrosis produced less
IFN- than subjects with mild disease. TNF-, IL-1, IL-4, IL-5,
IL-6, and IL-10 levels were not significantly different in the two
study groups; there was, however, a trend for an association of
fibrosis with higher levels of IL-1 ( p 
 0.1) and lower levels of
IL-10 ( p 
 0.13) in SEA-stimulated cultures. In unstimulated cul-
tures, low levels of IFN- ( p 
 0.05) and high levels of IL-1
( p 
 0.013) were significantly associated with fibrosis. Note that
there was also a trend for association of high IL-6 levels in un-
stimulated cultures of PBMC from subjects with disease; however,
this observation was not duplicated in the SEA-stimulated cultures.
Note that TNF- showed no association with fibrosis in the uni-
variate analysis, but it did so with logistic regression analysis (see
below). IFN- levels in individual cultures of subjects of the two
clinical groups are shown in Fig. 1.
Association of IFN- and TNF- production with PPF
Because various covariates could be confounders for the effects of
other covariates, the association of the covariates with the pheno-
type had to be tested simultaneously for all covariates that showed
a significant association with the clinical phenotype (age, gender,
infection levels, IFN-) or a trend for an association (IL-1, IL-4,
IL-10, IL-6). Moreover, covariates (IL-4, IL-5, TNF-) reported
by others to be associated with the disease phenotype or a related
phenotype were also tested in the analysis, although they showed
no evidence for an association in the univariate analysis. Of all
cytokines tested, only IFN- and TNF- showed a significant as-
sociation with fibrosis: the best model included IFN-, TNF-,
Table I. Stepwise regression analysis of the effects of gender, age, and
infection levels on the probability of a given individual to be affected by
advanced PPF (FII–III) or advanced PPF and portal hypertension
Gender Age
Infection
levels
Fibrosis II or IIIa p  104 p  104 p 
 0.01
ORb
 4 14.06
CI: 2.1–7.4 6.7–29.4
Fibrosis II or III and p  104 p  104 NS
portal hypertension
ORb
 12.5 21.7
CI: 2.1–72 2–239
a A total of 702 subjects had no or mild fibrosis; 61 had advanced (FII or FIII)
fibrosis; and 39 had advanced fibrosis with enlarged portal vein.
b OR compare males with females and the 35-year with the 10- to 20-year age
group.
c Confidence interval.
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age, and gender as covariates (Table III). Thus, in that model, the
associations of IFN- and TNF- were adjusted on age and gender
because the association of these cytokines with the disease phe-
notype varies (confounder effect) in the different age and gender
classes and in males vs females. Note that this model does not
adjust for intensity of infection because this covariate does not
improve the likelihood of the model and it was rejected from the
model by stepwise procedure.
Thus, in conclusion, IFN- showed a significant (inverse)
association ( p 
 0.01) with PPF; high levels of IFN- were
associated with a reduced risk of PPF. The OR that measures
the strength of the association of IFN- with fibrosis after
adjustment on other covariates with significant association with
disease (age, gender, and TNF-) is 0.11 (confidence interval,
0.03– 0.6). This grossly indicates that the risk of developing
severe disease is on average 9 times higher among low IFN-
producers than among high IFN- producers. Because the
association of infection levels with fibrosis was not significant
when tested in the presence of IFN-, OR were not adjusted on
infection levels. Forcing this covariate in the analysis had no
effect on the results of the analysis. The association of low
IFN- levels and advanced disease was also observed ( p 

FIGURE 1. IFN- production in SEA-stimulated cultures of PBMC
from subjects with no or mild fibrosis or with advanced fibrosis. Squares
represent individual data. The figure are the data from the 99 subjects
(studied in Tables II and III).
Table II. Cytokines produced in cultures of SEA-stimulated blood mononuclear cells from subjects with no or mild fibrosis (F0-I, n 
 75) and
subjects with advanced periportal fibrosis (FII–FIII, n 
 24)
Cytokinesa
Cultureb
Condition Hours
No or Mild Fibrosis Fibrosis FII or FIII
p1 p210–20 years 21–35 years 35 years 10–20 years 21–35 years 35 years
IL-1 48 46.5 1.6 1.6 ND 16.0 142.5 0.02
144c 24 30 180 325
SEA 48 7.0 9.0 5.0 8.3 27.0 23.0
SEA 120 67.0 12.5 44.0 1.6 13.5 59.0 0.1
135 102 127 16 68 199
IL-4 — 48 1.4 1.4 1.4 1.4 1.4 4.7 0.13
1.5 1.5 1.6 1.4 5.8 21.5
SEA 48 29.0 34.0 52.0 28.0 35.0 33.0
SEA 120 1.5 1.5 3.0 1.5 2.3 4.0
IL-5 SEA 120 3719.3 4501.1 6895.1 4057.1 7458.1 2849.6
IL-6 — 48 933.0 414.0 381.0 ND 508.0 2524.0 0.14
2059 958 1030 2654 4976
SEA 48 905.0 765.5 739.0 396.5 895.5 958.0
SEA 120 1214.0 777.5 791.0 409.0 681.5 721.0 0.2
2955 2387 1463 5753 1017 3210
IL-10 — 48 54.0 55.0 26.0 — 45.5 57.5
SEA 48 298.0 373.5 331.0 96.5 186.0 159.0 0.13
543 663 389 306 447 745
SEA 120 705.0 557.0 570.0 406.0 664.0 465.5 0.13
1094 813 909 626 855 830
TNF- — 48 93.5 97.0 52.0 ND 58.0 199.0
SEA 48 134.0 171.5 175.0 200.5 158.5 207.0
SEA 120 290.5 414.5 382.0 273.5 391.0 339.5 0.2
420 590 549 1152 441 407
IFN- — 48 0.2 0.2 0.2 ND 0.2 30.1 0.05
2.4 0.2 0.2 58 199
SEA 48 0.8 14.3 21.0 7.6 0.2 24.0
SEA 120 61.5 605.0 350.0 111.5 40.0 83.0 0.05 0.004
322 919 1129 337 78 372
a Cytokines were measured in 48- and 120-h supernatants of single cultures of SEA-stimulated cells and in 48-h cultures of unstimulated cells. Cytokine production is the
total production (production in unstimulated cultures was not subtracted). Cytokine levels in cultures of cells from both study groups were compared by the nonparametric
Wilcoxon test. The test was performed either on data from all three age groups and yield p1 values or on data from the 21- to 35-year and 35-year age groups and yield p2
values. p1 and p2 values are indicated when they are 0.2. Cytokine levels are median values.
b Culture conditions. Cells were cultured in medium without () additional stimulus or in the presence of SEA. Unstimulated culture supernatants were collected at 48 h only.
c The 75% upper percentile values are indicated in smaller italic numbers when p  0.2.
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0.003; adjusted OR 
 0.01) when the affected phenotype
combined PPF with portal hypertension (Table III).
TNF- was positively associated with PPF (Table III): high
TNF- levels were associated with a risk of FII-III on average 4
times higher in the high TNF- producers than in low TNF-
producers ( p
 0.05; OR
 4.6; confidence interval, 1–22). As for
other covariates in the analysis, the OR for TNF- was adjusted on
age, gender, and IFN- levels to take into account other covariates
significantly associated with advanced fibrosis. The association of
TNF- with disease was not significant ( p 
 0.065) when fibrosis
was combined with signs of portal hypertension probably because
of the smaller size of the PPF group. No other cytokines, including
IL-10 and IL-1, showed a significant association with disease in
the regression analysis.
The association of PPF with low IFN- production is illustrated
on Fig. 2, which shows the percentage of subjects with FII-III in
high and low IFN- classes, for the three classes of age used in the
multivariate analysis. Fig. 3 shows the percentage of subjects with
FII-III in low and high TNF- classes for the different high and
low IFN- classes.
High infections that are associated with PPF are associated
with a reduction of IFN- production
Because IFN- was strongly associated with protection against
PPF, we evaluated which factors could modulate IFN- levels.
IFN- levels were negatively correlated with infection intensities
( p 
 0.01; OR 
 0.15). This result is illustrated in Fig. 4. Intro-
ducing infection levels as one of the covariates tested in Table III
did not yield a better model, as discussed above, and IFN- was
still strongly associated with fibrosis. There were also statistically
significant differences in IFN- levels between Tama-Messeria and
Rawashda ( p
 0.05; OR
 0.15); this result is to be related to our
previous report of a trend for more severe disease in the Rawashda
(which produced on average less IFN-) than in the Tama-Mes-
seria (29).
Discussion
In 5–10% of infected subjects, S. mansoni causes a severe and
often lethal hepatic disease characterized by massive PPF that
leads to portal hypertension, esophageal varices, and ascites. In
some subjects, the liver and spleen are much enlarged. How hep-
atosplenomegaly and PPF are related is ill defined. Hepatospleno-
megaly is not always associated with PPF, and conversely PPF can
occur in subjects without hepatosplenomegaly. This was shown by
FIGURE 3. Proportion of grade II and III fibrosis in high and low
TNF- classes in the two low and high IFN- groups. Classes were defined
in Materials and Methods. IFN- and TNF- were measured in 48-h
(TNF-) and in 120-h (IFN-) cultures of PBMC stimulated with SEA.
Table III. Stepwise regression analysis of the effects of cytokine levels on the probability of a given individual to be affected by advanced PPF (FII–
III) or advanced PPF and portal hypertension
Gender Age IFN- TNF-
Fibrosis II or IIIa p 
 0.003 p  0.01 p 
 0.01 p 
 0.05
ORb
 6.7 12.5 0.11 4.6
CI: 2–40c 2.3–66 0.03–0.6 1–22
Fibrosis II or III, and PV  14mm ORb
 p 
 0.015 p 
 0.004 p 
 0.003 p  0.1
CI: 10.5 79 0.01
2–69c 2–300 0.001–0.4
a Number of subjects in the study: 75 subjects with mild or no fibrosis, 24 subjects with FII or FIII, and 13 subjects with FII, FIII and PV  14 mm.
b OR males with females, the 21- to 35-year age group with the 10- to 20-year age group, and the high with the low TNF-, and IFN- level groups. As described in Materials
and Methods, low and high cytokine groups are defined by the median value of TNF- and IFN- levels defined on the 10 years of age subjects, as in figures. Age groups
are 10–20, 21–35, and 35 years, as in figures.
c Confidence interval. Infection levels were not significantly associated with the probability of developing advanced disease in this model. Thus, OR are not adjusted on
infection levels. Forcing infection levels in the model did not change the results.
FIGURE 2. Proportion of grade II or III fibrosis in high and low IFN-
classes in the three age groups. Age and IFN- classes were defined in
Materials and Methods. The figure are the data from the 99 subjects studied
in Tables II and III. Classes were defined in Materials and Methods. IFN-
data are from 120-h cultures stimulated with SEA.
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others (29, 33) and also by our Taweela’s study: the distribution of
the subjects with advanced fibrosis (FII-III) in the four quartiles of
spleen size (smallest to largest size) was 15.8, 26.3, 29.4, and
33.3%; only the two upper quartiles could be considered as indi-
cating splenomegaly.
The factors that determine PPF in humans infected by S. man-
soni are poorly understood, except for the role of some genetic and
epidemiological factors. In contrast, the egg-induced pathology
has been extensively investigated in experimental models of in-
fection. Studies in mice, especially in animals deficient in certain
genes such as those of TGF-1, IL-4, IL-10, IL-12, Stat4, and
Stat6 (15, 20, 21, 34, 35), have shown that the egg granuloma and
hepatic fibrosis are markedly dependent on cytokine regulation.
How much of this work can be extended to the human disease is
unknown. Analysis of the role of cytokines in hepatic fibrosis in
infected humans is difficult for several reasons: such studies must
be conducted in the field on subjects with similar exposure to the
pathogen and with similar living habits; the analysis must be per-
formed on patients with active disease rather than subjects with
end stage disease. These studies must also evaluate nonimmuno-
logical covariates that are cofounders in the analysis. In addition,
immunological studies in infected humans can be performed only
on blood leukocytes, while sinusoidal Kupffer cells, stellate cells,
and endothelial cells are also important players in fibrosis (re-
viewed in Ref. 36). Nevertheless, there were several reasons to
believe that evaluating cytokine production on blood leukocytes
was a useful approach: 1) experimental studies conducted with
lymphocytes from various tissues have identified the principal cy-
tokines involved in the hepatic granuloma; 2) the regulation of
mouse schistosome egg granuloma is dependent on CD4 T lym-
phocytes; and 3) if polymorphisms in cytokine gene(s) account for
increased susceptibility to PPF, the effects of these mutations
should be observable on blood leukocytes.
Then the present study was performed to evaluate the cytokine
response of subjects with advanced liver disease in an attempt to
relate susceptibility to disease with an abnormal production of cy-
tokines that regulate granuloma and/or fibrosis in mice.
This work showed that production of IFN- in cultures of leu-
kocytes from subjects with FII-III is much lower than levels in
cultures from subjects with mild or no fibrosis. This association
between low IFN- levels and PPF was also confirmed after taking
into account the effects of important covariates such as gender and
age. Because both study groups have been living in similar con-
ditions for many years, including 15–20 years of frequent exposure
to schistosome infections, it is unlikely that differences in uniden-
tified environmental factors could explain these differences in
IFN- production. This result on the association between low
IFN- production and susceptibility to PPF must be analyzed in
light of the large body of evidence showing that IFN- is certainly
the most powerful and most active antifibrogenic cytokine in the
experimental schistosome egg granuloma (13–16, 37) and in many
injury-induced hepatic fibrosis (5–9, 12). IFN- acts at various
levels of fibrogenesis to limit accumulation of ECMP: it inhibits
the differentiation/activation of stellate cells, it inhibits production
of ECMP by stellate cells, it increases ECMP degradation by in-
ducing MPs, and it inhibits TIMPs. The association of low IFN-
production with fibrosis, added to observations in experimental
schistosomiasis and in studies on the regulation of ECMP produc-
tion, accumulation, and degradation, strongly suggests that PPF is
related to a decreased production of IFN-. In addition, the obser-
vations that IFN- levels are inversely related to infection and
account for the association of infection with PPF (Table III) also
suggest that high infections may contribute to PPF by down-mod-
ulating IFN-. Several studies (29, 38) including this one have
shown that high infection levels are associated with advanced fi-
brosis, especially in adolescents. High infections could contribute
in several ways to PPF, i.e., a higher number of eggs could in-
crease tissue inflammation or modulate cytokines that regulate fi-
brosis. An interesting finding is this effect is not dependent on
patient age because age was taken into account in the multivariate
analysis that tested the association between IFN- and infection
levels. The key role of IFN- in PPF was also suggested by the
existence of a major susceptibility locus for PPF closely linked to
IFNGR1 (27). A study in progress by our group has uncovered
various polymorphisms in IFNGR1 of these subjects. These poly-
morphisms are being tested for their association with PPF. It is,
however, too early to speculate more on the identity of the sus-
ceptibility alleles. Finally, the existence of a major gene does not
rule out other gene(s) in the genetic control of fibrosis; the relative
importance of these different genes in fibrosis will depend on the
study population. The present study suggests that susceptibility
alleles might also be found in the IFN- and TNF- pathway,
including in IFN- and TNF- genes.
A previous study in subjects with acute and chronic schistoso-
miasis (39) has suggested that IFN- and IL-10 cross-regulate each
other and that IL-10 is beneficial in patients with acute infections
or with hepatosplenomegaly. The present study did not detect an
association of IL-10 with fibrosis in the presence or in the absence
of either IFN- or TNF-. It should be noted, however, that there
was a trend ( p 
 0.13) for lower IL-10 production in both un-
stimulated and SEA-stimulated cultures of subjects with FII-FIII.
The study also failed to detect, in the regression analysis, a regu-
latory influence of IL-10 on IFN- production in culture of blood
mononuclear cells. This question, however, would be better ad-
dressed by inhibiting IL-10 production in cultures with mAb, as
done by others (39). This was not an objective of our study.
The association of TNF- with disease was detected in the pres-
ence of IFN- in the regression analysis; TNF- alone showed no
association with fibrosis. This and experimental results discussed
above suggest that TNF- could act on fibrosis by balancing the
protective effect of IFN-. TNF- has pleiotropic effects on the
FIGURE 4. IFN- produced in SEA-stimulated cultures of PBMC of
subjects with different infection levels. Squares indicate individual data or
identical data from different subjects. Horizontal bars represent median
value (picograms per milliliter).
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immune response against schistosomes: it restores the ability of T
cell-deficient mice to mount a granuloma around schistosome eggs
(24); it increases ECMP production by Kupffer cells (36); it stim-
ulates MP gene expression (40) and protects IL-12-vaccinated
mice against the deleterious effects of the granuloma (23); TNF-
also increases the production of NO, whose hypotensive effects
might benefit subjects with portal hypertension (41). Then, the
primary role of TNF- in schistosomiasis is a protective one. How-
ever, as in various pathologies, an imbalance between TNF- and
other regulatory cytokines may cause tissue damage. A possible
mechanism for this damage is an exacerbation of the granuloma by
overproduction of reactive oxygen species (4, 25, 26), as suggested
in experimental schistosomiasis (42). The association between
TNF- and clinical disease in schistosomiasis has also been found
in the sera and in the culture of blood mononuclear cells from
subjects with hepatosplenomegaly (43, 44).
That we did not observe an association between other cytokines
and PPF does not mean that in other conditions such an association
could not be uncovered. Table II indicates that IL-1, IL-10, and
IL-4 showed a trend (0.2  p  0.05) for an association with
fibrosis. Note, however, that these cytokines were rejected from
the regression analysis although the threshold value for inclusion
in the model was set up to 0.1. IL-1 data were the most sugges-
tive. IL-1 is a strong proinflammatory cytokine. It could aggra-
vate fibrosis by increasing chronic hepatic inflammation due to
eggs and worm Ags; IL-1 has not been reported to have direct
effect on fibrosis. As mentioned above, there was also a suggestion
that IL-10 was reduced in advanced fibrosis. It is unlikely that
protection against PPF is associated with Th2 cytokines, as re-
ported by Mwatha and colleagues for hepatosplenomegaly (43),
because of the strong association of this phenotype with IFN-.
Note also that the data in Table II ( p
 0.13) suggest that IL-4 was
augmented in unstimulated cultures of FII-FIII subjects. This may
relate to the likelihood that hepatosplenomegaly and PPF are dis-
tinct clinical phenotypes (33, 45).
In conclusion, this study shows that low production of IFN- is
associated with severe PPF in subjects living in an area endemic
for schistosomiasis and that a reduction in IFN-might account for
the higher risk of disease in subjects with high infections. Results
also indicate that TNF- might aggravate PPF in chronically in-
fected subjects.
It is now essential to determine whether these observations are
related to our previous work showing the existence of a strong
genetic control of PPF in certain subjects.
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